Comparative Pharmacology
Head-to-head clinical analysis: LASIX versus LASIX ONYU.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LASIX versus LASIX ONYU.
LASIX vs LASIX ONYU
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Furosemide inhibits the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle, reducing sodium, chloride, and water reabsorption and increasing urinary output.
Lasix (furosemide) inhibits the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle, reducing sodium, chloride, and water reabsorption.
20-80 mg IV or PO once or twice daily; maximum 600 mg/day IV or PO.
Furosemide 20-80 mg IV/PO once or twice daily; max 600 mg/day for IV, 80 mg/day for PO.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5-2 hours. In renal impairment (CrCl <20 mL/min), half-life may prolong to up to 2-4 hours; in end-stage renal disease or heart failure, may exceed 4 hours.
1.5-2.0 hours in normal renal function; prolonged to 10-15 hours in severe renal impairment (CrCl <10 mL/min); clinically significant accumulation risk with repeated dosing in renal disease.
Primarily renal excretion (50-80% as unchanged drug) via glomerular filtration and proximal tubular secretion; minor fecal elimination (<5%).
Primarily renal (50-80% as unchanged drug); biliary/fecal (20-30%); non-renal clearance accounts for up to 20%.
Category C
Category C
Loop Diuretic
Loop Diuretic